
Validea's Growth Investor model, based on Martin Zweig's strategy, rates Intuitive Surgical (ISRG) at 77%, just below the 80% threshold for strategic interest. While the large-cap medical equipment stock exhibits strong revenue and EPS growth with low debt, it notably fails on P/E ratio and earnings persistence, indicating it doesn't fully meet the strategy's criteria for accelerating earnings and reasonable valuation.
Intuitive Surgical, Inc. (ISRG) receives a 77% rating from Validea's Martin Zweig-based growth model, a score that indicates a mixed but generally positive fundamental picture, falling just shy of the 80% threshold for strategic interest. The analysis reveals a company with significant current momentum, passing key tests for current quarter earnings growth, sales growth rate, and a positive acceleration in EPS compared to both its historical rate and the prior three quarters. Furthermore, ISRG demonstrates balance sheet strength, as indicated by its passing score on the total debt-to-equity ratio, and shows favorable insider transaction activity. However, the model flags critical weaknesses that temper the overall outlook. Most notably, the stock fails on its P/E ratio, suggesting its valuation is considered too high to meet the strategy's criteria for a reasonable price. This is compounded by failures in 'earnings persistence' and 'earnings growth rate for the past several quarters', highlighting a lack of the consistent, accelerating growth track record that the Zweig model prioritizes.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment